DK0981327T3 - Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer - Google Patents

Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer

Info

Publication number
DK0981327T3
DK0981327T3 DK98921701T DK98921701T DK0981327T3 DK 0981327 T3 DK0981327 T3 DK 0981327T3 DK 98921701 T DK98921701 T DK 98921701T DK 98921701 T DK98921701 T DK 98921701T DK 0981327 T3 DK0981327 T3 DK 0981327T3
Authority
DK
Denmark
Prior art keywords
testosterone
administration
drug delivery
delivery devices
precursors
Prior art date
Application number
DK98921701T
Other languages
Danish (da)
English (en)
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of DK0981327T3 publication Critical patent/DK0981327T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK98921701T 1997-05-07 1998-05-07 Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer DK0981327T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
DK0981327T3 true DK0981327T3 (da) 2003-03-10

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98921701T DK0981327T3 (da) 1997-05-07 1998-05-07 Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer

Country Status (15)

Country Link
US (1) US6416780B1 (ja)
EP (1) EP0981327B1 (ja)
JP (1) JP2001524124A (ja)
CN (1) CN1184957C (ja)
AT (1) ATE227120T1 (ja)
AU (1) AU741482B2 (ja)
CA (1) CA2288046C (ja)
DE (1) DE69809222T2 (ja)
DK (1) DK0981327T3 (ja)
ES (1) ES2187024T3 (ja)
IL (1) IL132702A0 (ja)
NO (1) NO995419L (ja)
NZ (1) NZ501236A (ja)
PT (1) PT981327E (ja)
WO (1) WO1998050016A2 (ja)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ES2388731T5 (es) * 2002-03-27 2018-01-19 Warner Chilcott (Ireland) Limited Dispositivos de administración de fármacos mediante una matriz intravaginal
US8404272B2 (en) * 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
US8399013B2 (en) * 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
EP3470108A1 (en) 2004-07-02 2019-04-17 Mati Therapeutics Inc. Treatment medium delivery device for delivery of treatment media to the eye
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
ES2400091T3 (es) 2005-08-11 2013-04-05 Massachusetts Institute Of Technology Dispositivo de suministro de fármacos intravesical y método
BRPI0709672B8 (pt) 2006-03-31 2021-06-22 3088922 Inc implante ocular insersível em um lúmen ocular e método de distribuição de um agente terapêutico a um olho
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
BRPI0820800B8 (pt) * 2007-12-11 2021-06-22 Massachusetts Inst Technology dispositivo médico implantável para liberação controlada de droga
DK2249757T3 (en) * 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof.
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
BRPI0917135A2 (pt) * 2008-08-09 2015-11-10 Massachusetts Inst Technology dispositivo médico para extensão e retenção em uma vesícula seminal, duto ejaculatório, próstata ou vaso deferente de um paciente, uso de um elastômero reabsorvível, e, dispositivo de bomba osmótica.
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CN106928247A (zh) 2008-10-17 2017-07-07 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
US10543166B2 (en) 2009-06-26 2020-01-28 Taris Biomedical Llc Implantable drug delivery devices and methods of making the same
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
EP2663300B1 (en) 2011-01-10 2023-03-08 TARIS Biomedical LLC Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
EP3290024B1 (en) 2011-08-29 2019-04-17 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
CA2853439A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
EP2968880A1 (en) 2013-03-15 2016-01-20 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
CN105377888A (zh) 2013-03-15 2016-03-02 加利福尼亚大学董事会 纤维蛋白溶解的双反应性的有效的Kunitz抑制剂
KR102488491B1 (ko) 2013-08-19 2023-01-12 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
WO2015198104A1 (es) * 2014-06-28 2015-12-30 Laboratorios Andromaco S.A. Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, útil para la prevención de parto prematuro
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2016172704A1 (en) 2015-04-23 2016-10-27 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
DK3416964T3 (da) 2016-02-19 2021-02-22 Phoenix Molecular Designs 6-Oxo-N-(1-(benzyl)-1H-pyrazol-4-YL)-6,7,8,9-tetrahydropyrido[3',2':4,5]pyrrolo[1,2-A]pyrazin-2-carboxamid-derivater som P90 ribosomal S6 kinase- (RSK-) hæmmere til behandling af cancer
TN2018000385A1 (en) 2016-05-20 2020-06-15 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
BR112019011121A2 (pt) 2016-12-09 2019-10-01 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
UA127024C2 (uk) 2018-06-13 2023-03-15 Ксенон Фармасьютікалз Інк. Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів
CR20210095A (es) 2018-07-27 2021-06-01 Xenon Pharmaceuticals Inc Metodo para tratar la epilepsia
CN112638879B (zh) 2018-08-31 2024-06-18 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为治疗剂的用途
CN112638898B (zh) 2018-08-31 2024-04-09 泽农医药公司 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
AU2020222056A1 (en) 2019-02-11 2021-10-07 Phoenix Molecular Designs Crystalline forms of an RSK inhibitor
WO2023049364A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
AU2022351156A1 (en) 2021-09-24 2024-04-11 Xenon Pharmaceuticals Inc. Pyridinylacetamide derivatives as sodium channel activators
CA3232237A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridinyl derivatives as sodium channel activators
WO2023239729A1 (en) 2022-06-08 2023-12-14 Xenon Pharmaceuticals Inc. Pyridinamine derivatives and their use as potassium channel modulators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
AU538961B2 (en) * 1980-06-09 1984-09-06 Alex Harvey Industries Limited Intra-vaginal device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) * 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
CA2288046C (en) 2006-10-03
NO995419D0 (no) 1999-11-05
JP2001524124A (ja) 2001-11-27
NO995419L (no) 2000-01-07
WO1998050016A2 (en) 1998-11-12
PT981327E (pt) 2003-02-28
CN1255056A (zh) 2000-05-31
AU741482B2 (en) 2001-11-29
ATE227120T1 (de) 2002-11-15
AU7446998A (en) 1998-11-27
EP0981327A2 (en) 2000-03-01
DE69809222D1 (de) 2002-12-12
CA2288046A1 (en) 1998-11-12
EP0981327B1 (en) 2002-11-06
WO1998050016A3 (en) 1999-02-04
US6416780B1 (en) 2002-07-09
DE69809222T2 (de) 2003-08-14
CN1184957C (zh) 2005-01-19
IL132702A0 (en) 2001-03-19
NZ501236A (en) 2002-02-01
ES2187024T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
DK0981327T3 (da) Intravaginale lægemiddeltilførselsanordninger til indgivelse af testosteron og testosteronprecursorer
AU1227899A (en) Osmotic medicament releasing system
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
WO2003077972A3 (en) Implantable drug delivery system
WO2003028660A3 (en) Drug delivery devices and methods
DK0841903T3 (da) Orale farmaceutiske præparater indeholdende antimikrobielt virksomme aktivstoffer og sustained release pantoprazol
DK0799025T3 (da) Intravaginale stoftilførselsanordninger til tilførsel af 17beta-østradiolprækursorer
NO20016108L (no) Kontrollert frigivelse og smaks maskerende orale farmasöytiske sammensetninger
WO2002076426A3 (en) Intravaginal drug delivery devices for the administration of an antimicrobial agent
GB2338414A (en) Intravesical drug delivery system
BR0215262A (pt) Formas de dosagem com liberação sustentada de ordem zero e processo para a fabricação das mesmas
WO2002053128A3 (en) Sustained release drug delivery devices with multiple agents
AU6420798A (en) A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
HUP9902477A3 (en) Sustained delivery device and system of an active agent using an implantable system and method for producing of the device; a back-diffusion regulating outlet and a semipermeable plug
CA2292402A1 (en) Intra-vaginal device for pigs
PL352873A1 (en) New formulation
HK1032010A1 (en) Medicament formulation with a controlled release of an active agent.
ZA200106305B (en) Core tablet for controlled release of gliclazide after oral administration.
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
HK1060691A1 (en) Ion-strength independent sustained release pharmaceutical formulation
HRP20010684B1 (en) Directly compressible matrix for controlled release of single daily doses of clarithromycin
WO2002036077A3 (en) Once a day antihistamine and decongestant formulation
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases